1. Medtech Insight
  2. >>Geography
  3. >>Europe

Peripheral Artery Disease: Treatments And Diagnostics Poised For Growth

The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.

In July 2014, Boston Scientific Corp. CE marked its Ranger paclitaxel-coated balloon catheter for the treatment of peripheral artery disease (PAD), and immediately set about marketing the product throughout Europe. Drug-eluting balloons (DEBs) like the Ranger have become one of the most promising technologies for the treatment of PAD, and the Boston product joined a number of other DEBs already distributed in Europe for this indication, including Eurocor GMBH’s Freeway,Medtronic PLC’s IN.PACT, CR Bard Inc.’s Lutonix, and Cardionovum GMBH’s Legflow. Significantly, however, no DEB has so far been granted FDA approval for clinical use in the US, and the race is still on there to be first to market. (SeeAlso see "Drug-Coated Balloons Fuel Multibillion-Dollar Hopes" - Medtech Insight, 30 January, 2013.andAlso see "Re-Evaluating Growth Opportunities In Vascular Interventional Device Markets" - Medtech Insight, 28 February, 2014..)

According to the American Heart Association, approximately 8.5 million Americans are affected by PAD, with the highest prevalence occurring among elderly people, non-Hispanic blacks, and women. Medtronic puts the number...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Geography

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.